[go: up one dir, main page]

WO2018169153A1 - Composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium, pour le traitement et la prévention du syndrome de l'intestin perméable - Google Patents

Composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium, pour le traitement et la prévention du syndrome de l'intestin perméable Download PDF

Info

Publication number
WO2018169153A1
WO2018169153A1 PCT/KR2017/010349 KR2017010349W WO2018169153A1 WO 2018169153 A1 WO2018169153 A1 WO 2018169153A1 KR 2017010349 W KR2017010349 W KR 2017010349W WO 2018169153 A1 WO2018169153 A1 WO 2018169153A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
leaky gut
gut syndrome
cab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/010349
Other languages
English (en)
Korean (ko)
Inventor
함기백
박종민
한영민
박용진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gimedics Co ltd
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Original Assignee
Gimedics Co ltd
Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gimedics Co ltd, Industry Academic Cooperation Foundation of College of Medicine Pochon CHA University filed Critical Gimedics Co ltd
Publication of WO2018169153A1 publication Critical patent/WO2018169153A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Definitions

  • each tissue was scored on the basis of villi loss, ulceration, inflammation, and the like, when viewed pathologically as an animal tissue, and the results are shown in FIG. 6.
  • severe vili loss and inflammation were observed, with similar findings in the group receiving PPI.
  • the group receiving P-CAB showed more improvement in vili loss and inflammation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition capable de prévenir et de traiter efficacement le syndrome de l'intestin perméable ou le syndrome de l'intestin perméable induit par un médicament anti-inflammatoire non stéroïdien (AINS), la composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium (p-cab, pour "potassium-competitive acid blocker").
PCT/KR2017/010349 2017-03-16 2017-09-20 Composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium, pour le traitement et la prévention du syndrome de l'intestin perméable Ceased WO2018169153A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170033118A KR20180107341A (ko) 2017-03-16 2017-03-16 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물
KR10-2017-0033118 2017-03-16

Publications (1)

Publication Number Publication Date
WO2018169153A1 true WO2018169153A1 (fr) 2018-09-20

Family

ID=63522412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010349 Ceased WO2018169153A1 (fr) 2017-03-16 2017-09-20 Composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium, pour le traitement et la prévention du syndrome de l'intestin perméable

Country Status (2)

Country Link
KR (1) KR20180107341A (fr)
WO (1) WO2018169153A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100010412A1 (it) 2021-04-26 2022-10-26 Anseris Farma S R L Composizione per il trattamento dell’intestino irritabile e della sindrome metabolica correlata alle alterazioni della permeabilità intestinale.

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104258TA (en) * 2018-11-02 2021-05-28 4D Pharma Res Ltd Compositions comprising bacterial strains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056078A1 (en) * 2000-02-11 2001-12-27 Norton Healthcare Limited Novel method for treating gut disorders using polyanionic polyglycosides
KR20070057663A (ko) * 2005-12-01 2007-06-07 주식회사유한양행 위장관 점막 손상의 예방 또는 치료용 조성물
US8183211B2 (en) * 2000-05-19 2012-05-22 University Of Maryland, Baltimore Pharmaceutical compositions for inhibiting intestinal permeability
US20150057349A1 (en) * 2012-03-30 2015-02-26 Nestec S.A. 4-oxo-2-pentenoic acid and the health of the digestive tract
US20150258151A1 (en) * 2012-12-07 2015-09-17 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056078A1 (en) * 2000-02-11 2001-12-27 Norton Healthcare Limited Novel method for treating gut disorders using polyanionic polyglycosides
US8183211B2 (en) * 2000-05-19 2012-05-22 University Of Maryland, Baltimore Pharmaceutical compositions for inhibiting intestinal permeability
KR20070057663A (ko) * 2005-12-01 2007-06-07 주식회사유한양행 위장관 점막 손상의 예방 또는 치료용 조성물
US20150057349A1 (en) * 2012-03-30 2015-02-26 Nestec S.A. 4-oxo-2-pentenoic acid and the health of the digestive tract
US20150258151A1 (en) * 2012-12-07 2015-09-17 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA CANCER PREVENTION RESEARCH CENTER, CHA CANCER INSTITUTE, CHA UNIVERSITY ET AL.: "Indomethacin-induced Leaky Gut Syndrome Aggravated by Pantoprazole, but Not by Revaprazan: PPI Aggravated, but p-CAB Relieved NSAID-induced Intestinal Permeability", THE 10TH INTERNATIONAL GASTROINTESTINAL CONSENSUS SYMPOSIUM, vol. 4, 18 February 2017 (2017-02-18), pages 104 - 4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100010412A1 (it) 2021-04-26 2022-10-26 Anseris Farma S R L Composizione per il trattamento dell’intestino irritabile e della sindrome metabolica correlata alle alterazioni della permeabilità intestinale.

Also Published As

Publication number Publication date
KR20180107341A (ko) 2018-10-02

Similar Documents

Publication Publication Date Title
König et al. Human intestinal barrier function in health and disease
Melgar et al. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation
Chau et al. Malaria-associated L-arginine deficiency induces mast cell-associated disruption to intestinal barrier defenses against nontyphoidal Salmonella bacteremia
Choi et al. Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics
Barbara et al. Corrigendum: Inflammatory and microbiota-related regulation of the intestinal epithelial barrier
WO2018169153A1 (fr) Composition contenant en tant que principe actif un agent bloquant l'acide par compétition avec le potassium, pour le traitement et la prévention du syndrome de l'intestin perméable
Wu et al. The probiotic Lactobacillus casei Zhang-mediated correction of gut dysbiosis ameliorates peritoneal fibrosis by suppressing macrophage-related inflammation via the butyrate/PPAR-γ/NF-κB pathway
CN117165465A (zh) 用于改善肠屏障功能的植物乳杆菌菌株及其应用
Broquet et al. Interleukin-22 regulates interferon lambda expression in a mice model of pseudomonas aeruginosa pneumonia
IL265761B2 (en) Oral terlipressin compositions for use in treatment of ascites
Tomlinson et al. Interactions between lipopolysaccharide and the intestinal epithelium
Liu et al. Mechanism of ulcerative colitis-aggravated liver fibrosis: the activation of hepatic stellate cells and TLR4 signaling through gut-liver axis
Wang et al. The protective effect of l-theanine on the intestinal barrier in heat-stressed organisms
Yue et al. Promoting intestinal antimicrobial defense and microbiome symbiosis contributes to IL-22-mediated protection against alcoholic hepatitis in mice
Wang et al. Protective effect of zinc gluconate on intestinal mucosal barrier injury in antibiotics and LPS-induced mice
Qin et al. Arbutin alleviates intestinal colitis by regulating neutrophil extracellular traps formation and microbiota composition
Peng et al. Ellagic acid alleviates TNBS-induced intestinal barrier dysfunction by regulating mucin secretion and maintaining tight junction integrity in rats
Osman et al. Serosal but not mucosal endotoxin exposure increases intestinal permeability in vitro in the rat
Notebaert et al. In vivo imaging of NF‐κB activity during Escherichia coli‐induced mammary gland infection
CN114392264A (zh) 一种药物组合物及其在治疗溃疡性结肠炎中的应用
Nakadate et al. Progressive depletion of rough endoplasmic reticulum in epithelial cells of the small intestine in monosodium glutamate mice model of obesity
Ismail et al. Royal jelly protects against experimentally-induced ulcerative colitis in adult male albino rats: A histological study
Roberts et al. Ampicillin concentrations in pancreatic fluid bile obtained at endoscopic retrograde cholangiopancreatography (ERCP)
Amagase et al. Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen‐induced small intestinal lesions in rats
Kahl et al. Acute pancreatitis: treatment strategies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17900644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17900644

Country of ref document: EP

Kind code of ref document: A1